



1631

**PATENT**

Attorney Docket No. 896034605001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Elizabeth K. Barber  
Serial No. : 09/966,264  
Filed : September 28, 2001  
Title : **GENE EXPRESSION CONTROL DNA ELEMENT AND ASSOCIATED PROTEIN**  
Group Art Unit : 1631  
Examiner : Mary K. Zeman

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

This application claims the benefit of U.S. Provisional Application, Serial No. 60/237,079, filed September 30, 2000.

This statement is submitted in compliance with 37 CFR 1.56. A list of patent(s) and/or publications is set forth on the attached PTO-1449. A copy of each item listed is enclosed.

Any additional fees required for the proper filing of this Information Disclosure Statement should be withdrawn from the Jones Day Deposit Account No. 50-1432, Ref. 896034-605001.

Respectfully submitted,


*Barbara E. Arndt*

Barbara E. Arndt, Ph.D.  
Reg. No. 37,768

Jones Day  
North Point  
901 Lakeside Avenue  
Cleveland, Ohio 44114  
(216) 586-7575

I hereby certify that this correspondence  
is being deposited today with the United  
States Postal Service as first class mail in  
an envelope addressed to: Commissioner for  
Patents, P.O. Box 1450, Alexandria, VA

22313-1450  
on Dec 9/03  
By B. E. Arndt



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
896034605001

SERIAL NO.  
09/966,264

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT

Elizabeth K. Barber

FILING DATE GROUP

September 28, 2001 1631

U.S. PATENT DOCUMENTS

EXAMINER <u>INITIAL</u>	DOCUMENT NUMBER	DATE	NAME	CLASS/SUBCLASS	FILING DATE
----------------------------	--------------------	------	------	----------------	-------------

FOREIGN PATENT DOCUMENTS

EXAMINER <u>INITIAL</u>	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
----------------------------	-----------------	------	---------	-------	----------	-----------------------

EXAMINER <u>INITIAL</u>	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)				
----------------------------	-----------------	--	--	--	--	--

Atkinson, J. and R. Martin. Mutations to nonsense codons in human genetic disease: implications for gene therapy by nonsense suppressor tRNAs. *Nucleic Acids Research* 22(8), 1327-1334 (1994).

Buvoli, M. et al. Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes. *Molecular and Cellular Biology* 20(9), 3116-3124 (May 2000).

Kaufman, Randal J. Correction of genetic disease by making sense from nonsense. *Journal of Clinical Investigation* 104(4), 367-368 (August 1999).

Kessler, P.D. et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. *PNAS USA* 93, 14082-14087 (1996).

Kidwell M-G. and A.R. Wattam. An important step forward in the genetic manipulation of mosquito vectors of human disease. *PNAS* 95(7), 3349-3350 (March 1998).

Haecker, S.E. et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. *Human Gene Therapy* 7, 1907-1914 (1996).

Miralles, V.J. et al. The adenovirus inverted terminal repeat functions as an enhancer in a cell-free system. *J. Biol. Chem.* 264(18), 10763-10772 (1989).

Passos-Bueno, M.R. et al. Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. *Human Molecular Genetics* 3(6), 919-922 (1994).

Proudfoot, N.J. Transcriptional interference and termination between duplicated  globin gene constructs suggests a novel mechanism for gene regulation. *Nature* 322, 562-565 (1986).

Stedman, H. et al. Clinical protocol: phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy:     sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. *Human Gene Therapy* 11, 777-790 (March 2000).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.